Novartis AG — Director's Dealing 2018

Aug 14, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AILERON THERAPEUTICS INC (ALRN)
CIK: 0001420565
Period of Report: 2018-08-10

Reporting Person: Novartis Bioventures Ltd (10% Owner)
Reporting Person: NOVARTIS AG (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-08-10	Common Stock	S	5615	$2.44	Disposed	2442313	Direct
2018-08-13	Common Stock	S	1600	$2.36	Disposed	2440713	Direct

Footnotes

F1: Reflects sales of common stock executed in multiple transactions at prices ranging from $2.40 to $2.48. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F2: The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.

F3: Reflects sales of common stock executed in multiple transactions at prices ranging from $2.32 to $2.40. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.